Status:
COMPLETED
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
30+ years
Brief Summary
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
Eligibility Criteria
Inclusion
- Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion
- Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg
Key Trial Info
Start Date :
September 1 1999
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1039 Patients enrolled
Trial Details
Trial ID
NCT02236715
Start Date
September 1 1999
Last Update
September 11 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.